In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Dealmaking Quarterly Statistics, Q3 2012

A look at financing, M&A, and alliance activity July-September 2012

Executive Summary

Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.

You may also be interested in...



MacroGenics Strikes Second Oncology Partnership With Servier

The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.

Financings Of The Fortnight Notices Autumn Coincides With Increase In Option Deals

Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.

Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease

Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV003768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel